BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 20, 2025
Home » Authors » Sergio Held

Articles by Sergio Held

Colombia faces regulatory issues to take advantage of biodiversity for biotech

Oct. 20, 2015
By Sergio Held
RIO DE JANEIRO, Brazil – A series of regulatory challenges across Latin America are hindering the development of biotech projects in a region many see as being fertile with potential.
Read More

Wanted in LatAm: Biotech clusters to foster cooperation

Oct. 19, 2015
By Sergio Held
RIO DE JANEIRO – Latin America still doesn’t have biotech clusters, an important tool to boost economic growth and drive research, said industry experts at the BIO Latin American conference recently, adding that, to succeed, the region will have to create the environment and the ecosystem to develop such clusters.
Read More

2nd annual BIO Latin America kicks off with talk of barriers in Brazil

Oct. 16, 2015
By Sergio Held
RIO DE JANEIRO – With the participation of about 530 attendees, the second edition of BIO Latin America launched Thursday, bringing together biotech sector stakeholders to discuss opportunities in the sector that may be found and what barriers exist across the region.
Read More

Free access via Nuclear Medicine National Plan: Argentina gets first proton therapy center in LatAm with Invap, IBA agreement

Oct. 9, 2015
By Sergio Held

Mexico looks for ways to cope with avalanche of registration renewals

Oct. 5, 2015
By Sergio Held

Teva buys Mexico's generics powerhouse, Rimsa, for $2.3B

Oct. 2, 2015
By Sergio Held
BOGOTA, Colombia – Teva Pharmaceutical Industries Ltd. has agreed to acquire Representaciones e Investigaciones Médicas (Rimsa), of Mexico City, in a deal valued at $2.3 billion that will position the Israeli firm as the leading pharmaceutical company in Mexico, the second largest pharma market in Latin America behind Brazil.
Read More

Latin America looks to be a fertile landscape for telehealth initiatives

Sep. 30, 2015
By Sergio Held

Latin America: Colombia debating over mandatory automated external defibrillators

Sep. 22, 2015
By Sergio Held

Latin America + MENA countries = opportunities, but with challenges

Sep. 15, 2015
By Sergio Held
BOGOTA, Colombia – The links between the biotech sectors in Latin America and the Middle East and North Africa (MENA) remain shallow, even if industry stakeholders in both sides believe in the potential the relationships represent.
Read More

Latin America: Bayer premieres new manufacturing plant in Costa Rica for birth control devices

Sep. 4, 2015
By Sergio Held
Previous 1 2 … 15 16 17 18 19 20 21 22 23 … 31 32 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing